What would really be helpful for patients that run out of a particular mode of regimen such as endocrine, are trials that determine if a new drug using the same mechanism could control the disease. So in this case, beside trials comparing Amcenestrant against other regimens, there should be trials to determine if Amcenestrant work (to some degree) in patients who have exhausted all current endocrine drugs.
AMEERA-3: Amcenestrant in Endocrine-Resistant ER+/HER2− Advanced Breast Cancer
https://www.practiceupdate.com/conte.../141949/17/1/3